News
Phase 3 Results Offer Hope for Patients With Myelodysplastic Syndromes
Senior author of the study and Yale Cancer Center expert Amer Zeidan , MBBS, says the results showed that imetelstat, a first-in-class telomerase inhibitor, leads to durable red blood cell transfusion independence and a significant improvement in anemia in heavily transfused lower-risk MDS patients.